| sensitivity | Placebo N = 14 | Piroxicam N = 14 |
---|---|---|---|
Cytokines in pg/mL | Â | Â | Â |
IL-1beta | < 15 | 31.0 (21.0-112.5) | 14.9 (14.9-65.3) |
IL-1RA | < 20 | 245.0 (134.5-537.0) | 412.0 (177.5-615.0) |
IL-2 | < 15 | 14.9 (14.9-35.0) | 14.9 (14.9-14.9) |
IL-2R | < 40 | 248.0 (150.5-346.5) | 427.5 (207.5-595.0) |
IL-4 | < 5 | 4.9 (4.9-22.5) | 4.9 (4.9-10.5) |
IL-5 | < 5 | LO | LO |
IL-6 | < 5 | 22.0 (14.5-89.5) | 19.0 (6.5-160.5) |
IL-7 | < 25 | 24.9 (24.9-32.5) | 24.9 (24.9-40.5) |
IL-10 | < 3 | 5.0 (3.0-29.0) | 5.0 (3.0-6.0) |
IL-12 | < 6 | 169.0 (107.0-253.0) | 160.0 (115.0-274.3) |
IL-13 | < 6 | LO | LO |
IL-15 | < 25 | 39.0 (24.9-134.5) | 25.0 (24.9-60.0) |
IL-17 | < 20 | LO | LO |
GM-CSF | < 5 | 4.9 (4.9-44.0) | 4.9 (4.9-8.0) |
TNF-alpha | < 5 | 4.9 (4.9-9.5) | 4.9 (4.9-8.5) |
IFN-alpha | < 25 | 38.0 (25.5-66.5) | 41.5 (24.9-55.3) |
IFN-gamma | < 2 | LO | LO |
MCP-1/CCL2 | < 8 | 778.0 (561.0-1228.5) | 818.0 (458.5-1017.0) |
MIP-1alpha/CCL3 | < 15 | 44.0 (21.5-96.5) | 49.0 (30.0-66.5) |
MIP-1beta/CCL4 | < 10 | 123.0 (62.0-186.0) | 106.0 (56.0-192.0) |
RANTES/CCL5 | < 20 | HI | HI |
Eotaxin/CCL11 | < 5 | 76.0 (64.5-155.5) | 79.0 (63.8-127.5) |
IL-8/CXCL8 | < 3 | 132.0 (60.0-294.5) | 63.0 (53.5-276.0) |
MIG/CXCL9 | < 20 | 76.0 (61.0-186.0) | 133.0 (82.0-180.5) |
IP-10/CXCL10 | < 5 | 44.0 (32.0-65.0) | 53.0 (46.0-106.0) |
Serum Hsp, ng/mL | Â | Â | Â |
- Hsp27 | < 0.39 | 48.9 (14.3-72.3) | 20.1 (15.8-53.5) |
- Hsp70 | < 0.09 | 1.1 (0.6-1.7) | 1.5 (0.9-1.7) |
Intracellular Hsp, MFI (flow cytometry) | Â | Â | Â |
- Hsp27 | Â | Â | Â |
Lymphocytes - WHC | Â | 2.4 (1.6-4.3) | 2.4 (1.5-4.9) |
- 42°C (HC) |  | 5.2 (3.4-7.6) | 5.0 (4.1-6.5) |
Monocytes - WHC | Â | 28.1 (25.3-42.9) | 29.0 (16.0-43.1) |
- 42°C (HC) |  | 40.3 (29.2-51.2) | 41.2 (29.8-59.9) |
- Hsp70 | Â | Â | Â |
Lymphocytes - WHC | Â | 2.1 (1.6-4.4) | 2.5 (1.5-4.3) |
- 42°C (HC) |  | 11.9 (7.8-14.9) | 13.5 (5.1-18.0) |
Monocytes - WHC | Â | 13.5 (8.2-26.8) | 12.7 (8.1-18.8) |
- 42°C (HC) |  | 244.1 (149.9-332.1) | 211.0 (160.5-343.4) |